Restoring Suppressed Hormones in ICU Patients With Growth Hormone and Thyroid Peptides
Continuous GHRP-2 and TRH infusions reactivated suppressed growth hormone and thyroid hormone secretion in 20 critically ill patients, restoring more normal pulsatile hormone patterns.
Quick Facts
What This Study Found
Combined GHRP-2 and TRH infusion most effectively reactivated both pulsatile GH secretion and the thyrotropic axis in 20 prolonged critically ill patients, with effects exceeding either agent alone.
Key Numbers
How They Did This
Randomized trial in 20 adult critically ill patients. Continuous IV infusions of TRH, GHRP-2, GHRH alone and in combinations were administered. Pulsatile GH, TSH, thyroid hormones, and IGF-1 were measured over treatment periods.
Why This Research Matters
The hormonal suppression in critical illness is not just a consequence of being sick — it actively worsens outcomes by driving muscle loss and metabolic dysfunction. Correcting it with peptide therapy could improve survival.
The Bigger Picture
Critical illness endocrinology represents a major frontier in ICU medicine. Rather than just supporting organs and fighting infections, correcting hormonal dysfunction could fundamentally change ICU outcomes by maintaining the body's ability to heal itself.
What This Study Doesn't Tell Us
20 patients — small sample. Hormonal endpoints, not clinical outcomes. Heterogeneous ICU population. Continuous IV infusion is resource-intensive for routine clinical use.
Questions This Raises
- ?Do the restored hormone levels translate to better clinical outcomes?
- ?Can simpler dosing regimens (subcutaneous GHRP-2) achieve similar results?
- ?Should hormonal therapy begin early in critical illness to prevent endocrine suppression?
Trust & Context
- Key Stat:
- 20 ICU patients Combined GHRP-2 + TRH restored both pulsatile GH and thyroid hormone secretion more effectively than either agent alone
- Evidence Grade:
- Moderate evidence from a randomized trial with clear hormonal endpoints in a clinically relevant population, limited by small size and surrogate outcomes.
- Study Age:
- Published in 1998 by the Leuven critical illness endocrinology group. Their research has continued with landmark studies on hormonal management in the ICU.
- Original Title:
- Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
- Published In:
- The Journal of clinical endocrinology and metabolism, 83(2), 309-19 (1998)
- Authors:
- Van den Berghe, G(10), de Zegher, F(5), Baxter, R C(3), Veldhuis, J D, Wouters, P, Schetz, M, Verwaest, C, Van der Vorst, E, Lauwers, P, Bouillon, R, Bowers, C Y
- Database ID:
- RPEP-00501
Evidence Hierarchy
Frequently Asked Questions
Why are hormones suppressed in critical illness?
The body's neuroendocrine system partially shuts down during prolonged illness, possibly as a survival mechanism. But this suppression also drives muscle wasting and impairs healing, creating a vicious cycle.
Could these peptides become standard ICU treatment?
This study provides proof-of-concept that the hormonal suppression can be corrected. Whether doing so improves survival and recovery requires larger clinical trials, which have been conducted subsequently.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00501APA
Van den Berghe, G; de Zegher, F; Baxter, R C; Veldhuis, J D; Wouters, P; Schetz, M; Verwaest, C; Van der Vorst, E; Lauwers, P; Bouillon, R; Bowers, C Y. (1998). Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.. The Journal of clinical endocrinology and metabolism, 83(2), 309-19.
MLA
Van den Berghe, G, et al. "Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.." The Journal of clinical endocrinology and metabolism, 1998.
RethinkPeptides
RethinkPeptides Research Database. "Neuroendocrinology of prolonged critical illness: effects of..." RPEP-00501. Retrieved from https://rethinkpeptides.com/research/van-1998-neuroendocrinology-of-prolonged-critical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.